TAKHZYRO
- Business Wire
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
− Analysis of Safety and Efficacy for up to 2.5 years with TAKHYZRO is Consistent with Initial Period of Treatment,…
Read More » - Business
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
Osaka, Japan: — Lanadelumab is an investigational monoclonal antibody for the preventive treatment of hereditary angioedema (HAE) in patients 12…
Read More » - Business
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
Shanghai, China & Osaka, Japan: − TAKHZYRO is the first approved modern therapy for the preventive treatment of hereditary angioedema…
Read More » - World
Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema
Osaka, Japan: Study Results Showed Long-term Findings Consistent with the Known Safety Profile of TAKHZYRO with Reductions in the Rate…
Read More »